Showing 271-280 of 4926 results for "".
FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.Lashing Out: A New Direction in Lash Treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/lashing-out-a-new-direction-in-lash-treatment/20743/New eyelash ptosis treatment means no more lash curlers.Visible Benefit of Compression for Leukocytoclastic Vasculitis
https://practicaldermatology.com/columns/clinical-focus-1/visible-benefit-of-compression-for-leukocytoclastic-vasculitis/24212/The use of compression stockings has been suggested in the management of leukocytoclastic vasculitis (LCV), however there are a lack of studies in the literature that provide evidence of the benefit of compression therapy in the treatment of LCV.1,2 Here we present a case that visually demonstratesThe Use of Lasers and Energy-Based Devices in Patients with Richly Pigmented Skin
https://practicaldermatology.com/programs/practical-dermatology/the-use-of-lasers-and-energy-based-devices-in-patients-with-richly-pigmented-skin/18199/In the last of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Andrew Alexis, MD, a dermatologist from New York City and the President of the Skin of Color Society, Corey Hartman, MD, a dermatologist in Birmingham, Alabama, and Janiene Luke, MD, a dermatoloHair Loss in Patients With Diverse Skin Tones
https://practicaldermatology.com/programs/practical-dermatology/hair-loss-in-patients-with-skin-of-color/18194/In this first installment of a two-part episode of The Practical Dermatology Podcast, Brooke Jackson, MD, founder and owner of Skin Wellness Dermatology Associates in Durham, NC, and a dermatologic surgeon and dermatologist, speaks about hair loss in patients with diverse skin tones, the timing of hISDPA: Dr. Lio on Alternative and Innovative Approaches
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-lio-alternative-and-innovative-approaches/27066/Practical Dermatology Editorial Board member Peter Lio, MD, discusses the presentation that he and Tracee Blackburn, PA-C, gave about alternative and innovative approaches in dermatology, as well as the importance of educational engagement between physician assistants and dermatologists, at the IlliDermWireTV: Birch Triterpenes Gel Gets FDA Approval for EB, VTE Risk is Lower in Patients with AD, and Are Topical Steroids Affecting Bone Health?
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-birch-triterpenes-t-gel-gets-fda-approval-for-eb-vte-risk-is-lower-in-patients-with-ad-and-are-topical-steroids-affecting-bone-health/20233/A birch bark extract topical from Chiesi Global Rare Diseases represents the latest in treatment approvals for epidermolysis bullosa. Patients with atopic dermatitis may have a decreased risk for developing venous thromboembolism. Commonly prescribed topical steroids may raise some patients' risk foLong-term Management Strategies for AD, Melasma, and More
https://practicaldermatology.com/topics/psoriasis/long-term-management-strategies-for-ad-melasma-and-more/20801/After the acute treatment phase, experts urge a long-view on management.How Will You Be Remembered? Building a Work Legacy
https://practicaldermatology.com/topics/practice-management/how-will-you-be-remembered-building-a-work-legacy/21124/Five attributes are commonly shared by leaders who eventually become legends.Shifting Paradigms on Lentigo Maligna
https://practicaldermatology.com/conferences/maui-derm-2024/shifting-paradigms-on-lentigo-maligna/20255/According to Ashfaq Marghoob, MD, current research supports individualizing treatment of lentigo maligna (LM) based on what is the best therapeutic option, from active surveillance to surgery to radiation to imiquimod.